Each filer's latest filing for 82024L103 since 12/18/2024, largest first.
| Filer | % of Class | Filed | ||
|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. 13G/A | 14.3% |
11/16/2026
Event 9/30/2026
|
||
|
Orbimed Advisors LLC
13D/A
|
10.0% |
6/15/2026
Event 6/11/2026
|
||
| Orbimed Advisors LLC | 10.0% | |||
| OrbiMed Capital GP IX LLC | 8.3% | |||
| OrbiMed Genesis GP LLC | 1.7% | |||
|
Redmile Group, LLC
13D/A
|
9.9% |
7/17/2026
Event 7/15/2026
|
||
| Redmile Group, LLC | 9.9% | |||
| Jeremy C. Green | 9.9% | |||
| Redmile Biopharma Investments II, L.P. | 8.1% | |||
|
Prosight Management, LP
13G/A
|
9.9% |
11/13/2025
Event 9/30/2025
|
||
| Prosight Management, LP | 9.9% | |||
| Prosight Fund, LP | 0.9% | |||
| Prosight Plus Fund, LP | 4.9% | |||
| Prosight Partners, LLC | 9.9% | |||
| W. Lawrence Hawkins | 9.9% | |||
|
Adage Capital Partners GP, L.L.C.
13G/A
|
9.8% |
2/12/2025
Event 12/31/2024
|
||
| Adage Capital Management, L.P. | 9.8% | |||
| Adage Capital Partners GP, L.L.C. | 0% | |||
| Robert Atchinson | 9.8% | |||
| Phillip Gross | 9.8% | |||
| BlackRock, Inc. 13G | 5.3% |
10/27/2026
Event 9/30/2026
|
||
| Under 5%, checked the "5 percent or less" box, or amended by a later filing (2) | ||||
|
Deep Track Capital, LP
13G/A
|
4.9% |
11/16/2026
Event 9/30/2026
|
||
| Deep Track Capital, LP | 4.9% | |||
| Deep Track Biotechnology Master Fund, Ltd. | 4.9% | |||
| David Kroin | 4.9% | |||
| Vanguard Group Inc 13G/A | 4.5% |
7/29/2025
Event 6/30/2025
|
||
| Period | Filers | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 119 | 90.9 M | $619M |
| 2026 Q2 | 103 | 83.8 M | $581M |
| 2026 Q1 | 84 | 56.1 M | $360M |
| 2025 Q4 | 65 | 42.5 M | $155M |
| 2025 Q3 | 57 | 36.4 M | $87.0M |
| 2025 Q2 | 63 | 28.7 M | $22.7M |
| 2025 Q1 | 76 | 31.2 M | $29.6M |
| 2024 Q4 | 76 | 31.6 M | $38.3M |
| 2024 Q3 | 79 | 36.3 M | $125M |
| 2024 Q2 | 75 | 34.2 M | $132M |
| 2024 Q1 | 71 | 31.5 M | $281M |
| 2023 Q4 | 60 | 29.1 M | $208M |
| 2023 Q3 | 42 | 19.9 M | $30.2M |
| 2023 Q2 | 43 | 20.1 M | $62.6M |
| 2023 Q1 | 50 | 20.4 M | $59.8M |
| 2022 Q4 | 49 | 20.4 M | $46.9M |
| 2022 Q3 | 64 | 20.7 M | $56.0M |
| 2022 Q2 | 73 | 21.4 M | $87.0M |
| 2022 Q1 | 78 | 24.0 M | $102M |
| 2021 Q4 | 84 | 24.2 M | $210M |
| 2021 Q3 | 71 | 25.8 M | $525M |
| 2021 Q2 | 68 | 25.9 M | $750M |
| 2021 Q1 | 57 | 23.4 M | $683M |
| 2020 Q4 | 60 | 22.7 M | $1.17B |